Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

A Sanofi official told lawmakers the company ... Only Metformin, another diabetes drug, was prescribed more frequently in 2023. Hal Andrews, CEO at Trilliant Health, said as new drugs soared ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...